AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7909099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 82
Study 7909099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 2439559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular ectopic activity (greater than or equal to 10 ventricular premature beats/h or pairs, ventricular tachycardia or multiform complexes)
Number of subjects: 3290
Study 2439559 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ventricular ectopic activity
Number of subjects: 3290
Study 2439559 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven categoric definitions of ventricular ectopic activity
Number of subjects: 3290
Study 2439559 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical criteria (ST depression, cardiomegaly, prior infarction)
Number of subjects: 3290
Study 2439559 — intervention group
Group type: COMPARATOR
Intervention: Control group (1,640 patients randomized to placebo therapy)
Number of subjects: 3290
Study 31436843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health promotion intervention (classroom session, information materials, free condom distribution)
Number of subjects: 500
Study 31436843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 500
Study 29718329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridinilazole (200 mg twice daily)
Number of subjects: 100
Study 29718329 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg four times daily)
Number of subjects: 100
Study 29718329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 100
Study 29718329 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100
Study 27697550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold condition (local torso cooled)
Number of subjects: 44
Study 27697550 — intervention group
Group type: COMPARATOR
Intervention: Thermal neutral condition
Number of subjects: 44
Study 24391142 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/Amlodipine 5 mg (T80/A5)
Number of subjects: 324
Study 24391142 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg (A5)
Number of subjects: 324
Study 23548219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraumbilical vein oxytocin injection (10 IU, 1 mL)
Number of subjects: 178
Study 21139155 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection with laboratory-prepared, amplified collagen-producing cells derived from dermal fibroblasts and suspended in autologous plasma
Number of subjects: 46
Study 21139155 — intervention group
Group type: COMPARATOR
Intervention: Autologous plasma alone
Number of subjects: 46
Study 18511473 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT, vitamin D(3) and calcium
Number of subjects: 88
Study 18511473 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D(3) and calcium alone
Number of subjects: 88
Study 18511473 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 88
Study 16595018 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression information website
Number of subjects: 414
Study 16595018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural skills training website (CBT)
Number of subjects: 414
Study 16595018 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 414
Study 12699514 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchangers (HMEs) with fresh gas flows of 1.0, 3.0, or 6.0 l min‐1
Number of subjects: 90
Study 12699514 — intervention group
Group type: COMPARATOR
Intervention: Control group without HMEs with fresh gas flows of 1.0, 3.0, or 6.0 l min‐1
Number of subjects: 90
Study 12699514 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchangers (HMEs)
Number of subjects: 90
Study 12699514 — intervention group
Group type: COMPARATOR
Intervention: Control group without HMEs
Number of subjects: 90
Study 10967613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iodised oil (1 ml Lipiodol Ultrafluide, 490 mg I)
Number of subjects: 197
Study 8813041 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1153
Study 8813041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1153
Study 8813041 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (nonischemic cardiomyopathy)
Number of subjects: 1153
Study 8813041 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonischemic cardiomyopathy)
Number of subjects: 1153
Study 8813041 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (ischemic heart disease)
Number of subjects: 1153
Study 8813041 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ischemic heart disease)
Number of subjects: 1153
Study 1430283 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated glutaraldehyde‐crosslinked human collagen membrane (test)
Number of subjects: 19
Study 1430283 — intervention group
Group type: COMPARATOR
Intervention: Flap reflection alone (control)
Number of subjects: 19
Study 2430825 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum
Number of subjects: 32
Study 2430825 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin
Number of subjects: 32
Study 29813111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) within 4.5 hours after NA-CRAO
Number of subjects: 20
Study 29813111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 20
Study 29813111 — intervention group
Group type: COMPARATOR
Intervention: Conservative standard treatment (CST) from the EAGLE trial
Number of subjects: 20
Study 27974857 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Parents and Babies (IYPB) program
Number of subjects: 112
Study 27974857 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study 25020008 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention (Stanley and Brown, 2012)
Number of subjects: 0
Study 22690890 — intervention group
Group type: EXPERIMENTAL
Intervention: CSD communication skills training intervention (2 hour teaching session, deliberate practice, online modules, self-reflection, booster training session)
Number of subjects: 0
Study 22690890 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinical rotations alone)
Number of subjects: 0
Study 21246840 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group 1 (electroacupuncture at Jiaji (EX‐B 2) points of T5‐T7 and Shenshu (BL 23))
Number of subjects: 120
Study 21246840 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group 2 (electroacupuncture at Neiguan (PC 6), Shenmen (HT 7) and Zusanli (ST 36))
Number of subjects: 120
Study 21246840 — intervention group
Group type: COMPARATOR
Intervention: Simulation group (analog electrical stimulation at Zusanli (ST 36) and Sanyinjiao (SP 6))
Number of subjects: 120
Study 21246840 — intervention group
Group type: COMPARATOR
Intervention: Blank group (no therapy applied)
Number of subjects: 120
Study 18272507 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop stimulation (CLS)
Number of subjects: 131
Study 18272507 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer sensor (AS)
Number of subjects: 131
Study 18428192 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 37) participated in 150 min/wk of supervised gym‐based and home‐based aerobic exercise for 6 months.
Number of subjects: 75
Study 18428192 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (n = 38) instructed to maintain current physical activity level.
Number of subjects: 75
Study 18428192 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 37)
Number of subjects: 75
Study 18428192 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (n = 38)
Number of subjects: 75
Study 15196285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP) 200 microg once daily
Number of subjects: 471
Study 15196285 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 471
Study 15196285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral loratadine (LOR) 10 mg once daily
Number of subjects: 471
Study 11723015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid-lowering strategy
Number of subjects: 402
Study 11723015 — intervention group
Group type: COMPARATOR
Intervention: Moderate lipid-lowering strategy
Number of subjects: 402
Study 9161362 — intervention group
Group type: EXPERIMENTAL
Intervention: Softest interface (EVA foam)
Number of subjects: 12
Study 9161362 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiffest interface (EVA foam)
Number of subjects: 12
Study 9161362 — intervention group
Group type: COMPARATOR
Intervention: Rigid surface
Number of subjects: 12
Study 7962376 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg
Number of subjects: 32
Study 7962376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3498877 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (one dose a day)
Number of subjects: 232
Study 3498877 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (two doses a day)
Number of subjects: 232
Study 3498877 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (three doses a day)
Number of subjects: 232
Study 3498877 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (two doses a day) with written instruction sheet and advice
Number of subjects: 232
Study 30982100 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (25 billion CFU Lactobacillus acidophilus, Bifidobacterium bifidum, and Bifidobacterium animalis subs p. Lactis) for 28 days
Number of subjects: 24
Study 30982100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30982100 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 24
Study 28934800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular pulsed radiofrequency (PRF)
Number of subjects: 40
Study 28934800 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular corticosteroid injection (ICI)
Number of subjects: 40
Study 25582182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU) at birth
Number of subjects: 29
Study 25582182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 25582182 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breastfed infants
Number of subjects: 29
Study 23559419 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual sub‐segmental analysis (VSSA)
Number of subjects: 161
Study 21900640 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude whole body vibration with resistive exercise
Number of subjects: 14
Study 21900640 — intervention group
Group type: COMPARATOR
Intervention: Control (head-down bed rest without intervention)
Number of subjects: 14
Study 19491910 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, a B‐cell‐depleting anti‐CD20 monoclonal antibody
Number of subjects: 0
Study 19491910 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 16733162 — intervention group
Group type: EXPERIMENTAL
Intervention: 10F, 15F, and 19F Blake drains (group A)
Number of subjects: 189
Study 16733162 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest drains (group B)
Number of subjects: 189
Study 15593174 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 431
Study 15593174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 15593174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Doxycycline and Placebo)
Number of subjects: 431
Study 11380528 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (1 mg)
Number of subjects: 24
Study 11380528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11380528 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year oral melatonin treatment
Number of subjects: 24
Study 8985189 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination of health care workers (HCWs)
Number of subjects: 1059
Study 8985189 — intervention group
Group type: COMPARATOR
Intervention: Vaccination of patients
Number of subjects: 1059
Study 8250309 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA) with 2.5-5 mg of plain bupivacaine 0.5%
Number of subjects: 50
Study 8250309 — intervention group
Group type: COMPARATOR
Intervention: Single-dose spinal anesthesia (SS) with 20 mg of plain bupivacaine 0.5%
Number of subjects: 50
Study 8250309 — intervention group
Group type: COMPARATOR
Intervention: Single-dose spinal anesthesia (SS)
Number of subjects: 50
Study 3300967 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA)
Number of subjects: 64
Study 3300967 — intervention group
Group type: EXPERIMENTAL
Intervention: Iproplatin (CHIP)
Number of subjects: 64
Study 29608107 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 161
Study 24934544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g DHA (22:6) and 0.6 g EPA (20:5) for 6 months
Number of subjects: 40
Study 24934544 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study 22425127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg) and/or Tamsulosin (0.4 mg)
Number of subjects: 0
Study 22425127 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21039311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 0
Study 21039311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 0
Study 21039311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 0
Study 21039311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18827299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 49
Study 18827299 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 16521850 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g L-Carnitine L-tartrate (LCLT) daily for 4 weeks
Number of subjects: 15
Study 16521850 — intervention group
Group type: COMPARATOR
Intervention: 3 g placebo (P) daily for 4 weeks
Number of subjects: 15
Study 16521850 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g L-Carnitine L-tartrate (LCLT)
Number of subjects: 15
Study 12456937 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled (cotton spandex swaddle)
Number of subjects: 26
Study 12456937 — intervention group
Group type: COMPARATOR
Intervention: Unsaddled
Number of subjects: 26
Study 9733448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine 20 mg/m2 body surface area per day for 3 consecutive days
Number of subjects: 26
Study 9733448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine 30 mg/m2 body surface area per day for 3 consecutive days
Number of subjects: 26
Study 8018458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg four times daily
Number of subjects: 24
Study 8018458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg four times daily
Number of subjects: 24
Study 8018458 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg four times daily
Number of subjects: 24
Study 8018458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2685953 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-rich yeast (100 micrograms/day)
Number of subjects: 81
Study 2685953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 4318020 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (800 mg)
Number of subjects: 4
Study 4318020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloral phenazone (1,300 mg)
Number of subjects: 4
Study 4318020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandrax (methaqualone 250 mg and diphenhydramine 25 mg)
Number of subjects: 4
Study 4318020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31928313 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal
Number of subjects: 0
Study 31928313 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation
Number of subjects: 0
Study 30032842 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 437
Study 30032842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 26455343 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + lines (left atrial roof line, mitral isthmus line, and tricuspid isthmus line)
Number of subjects: 122
Study 26455343 — intervention group
Group type: COMPARATOR
Intervention: PVI-only
Number of subjects: 122
Study 26455343 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + lines
Number of subjects: 122
Study 26455343 — intervention group
Group type: COMPARATOR
Intervention: PVI + lines and PVI-only
Number of subjects: 122
Study 24770930 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel vascular polyester prosthesis coated with a resorbable polymer
Number of subjects: 24
Study 22486193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% alcohol-free chlorhexidine mouthwash applied twice a day for 30 days
Number of subjects: 70
Study 22486193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22486193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% alcohol-free chlorhexidine mouthwash
Number of subjects: 70
Study 19760232 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) with a minimum threshold post-ablation margin of 0.4 cm in HCC group
Number of subjects: 83
Study 19760232 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) with a minimum threshold post-ablation margin of 0.4 cm in colorectal liver metastases group
Number of subjects: 83
Study 18481115 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing by telephone (3 calls at intervals of 2 months)
Number of subjects: 147
Study 18481115 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing by telephone
Number of subjects: 147
Study 16617767 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium cylinder-design cage
Number of subjects: 46
Study 16617767 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon box-design cage
Number of subjects: 46
Study 17638141 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 72
Study 17638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer lower-limb motor score and Berg Balance score
Number of subjects: 72
Study 17638141 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse and blood pressure pre- and posttesting
Number of subjects: 72
Study 11332356 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamins C and E) and Calcium Channel Blockers (nimodipine)
Number of subjects: 120
Study 11332356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidants or calcium channel blockers)
Number of subjects: 120
Study 8935814 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine withdrawal with addition of neuroleptic
Number of subjects: 83
Study 8935814 — intervention group
Group type: COMPARATOR
Intervention: Clozapine withdrawal without addition of neuroleptic
Number of subjects: 83
Study 8935814 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine withdrawal with addition of cyproheptadine
Number of subjects: 83
Study 8935814 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic discontinuation of clozapine in neuroleptic‐resistant patients
Number of subjects: 83
Study 1387844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungoid Tincture
Number of subjects: 10
Study 1387844 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 10
Study 2998785 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 5
Study 2998785 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 5
Study 30834652 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow rate reduction of 100 mL/min to a minimum of 300 mL/min
Number of subjects: 102
Study 30834652 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 102
Study 29080069 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Aminosalicylic Acid (5-ASA) 500 mg capsules, four times daily for 6 weeks
Number of subjects: 17
Study 29080069 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Aminosalicylic Acid (5-ASA)
Number of subjects: 17
Study 29080069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 27426231 — intervention group
Group type: EXPERIMENTAL
Intervention: LFCN block with 8 ml of 0.75% ropivacaine
Number of subjects: 60
Study 27426231 — intervention group
Group type: COMPARATOR
Intervention: LFCN block with 8 ml of saline
Number of subjects: 60
Study 25242806 — intervention group
Group type: EXPERIMENTAL
Intervention: NEUROvitalis (structured training)
Number of subjects: 65
Study 25242806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentally fit (unstructured training)
Number of subjects: 65
Study 25242806 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 65
Study 22824201 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg everolimus daily
Number of subjects: 0
Study 22824201 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg everolimus daily
Number of subjects: 0
Study 22824201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20731976 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 957
Study 20731976 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 957
Study 20731976 — intervention group
Group type: COMPARATOR
Intervention: Referral brochure
Number of subjects: 957
Study 18056556 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced communication intervention (five 2 1/2‐hour sessions)
Number of subjects: 1115